本文へ移動
cccskills
無料GitHub で公開

pdm-delivery-timing

Recommends early delivery based on individualized risk assessment rather than expectant management for pregnant patients with preexisting diabetes mellitus (PDM). Consider when evaluating delivery timing in the presence of diabetes‑related complications, suboptimal glycemia, abnormal fetal growth, or maternal comorbidities that may increase perinatal risk beyond 38 weeks gestation.

インストール方法を見る

含まれるファイル(1)

  • SKILL.md2.8 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Early Delivery Based on Risk Assessment in Preexisting Diabetes

STEP 1 — Gather Information

Collect maternal diabetes type and duration, history of complications (nephropathy, retinopathy, cardiovascular disease), glycemic control (HbA1c, time in range, CGM metrics), obstetric history (prior stillbirth, preterm birth), fetal assessment (ultrasound estimated fetal weight, amniotic fluid index, Doppler), maternal comorbidities (hypertension, obesity, thyroid disease), and current gestational age.

STEP 2 — Rule In / Rule Out

Is there any high‑risk feature present (e.g., prior perinatal loss, hypertensive disorder, nephropathy, fetal growth abnormality, persistent hyperglycemia despite therapy)? If yes → proceed to risk stratification; if no → continue expectant management with weekly review.

STEP 3 — Classify or Stratify

Stratify risk into high (any major complication or poor glycemia) versus low (no complications, glycemia within target, normal fetal growth). High risk suggests consideration of delivery between 37+0 and 38+6 weeks; low risk permits expectant management up to 39+0 weeks.

STEP 4 — Decide

For high‑risk patients, schedule delivery at the earliest gestational age deemed safe based on individual risk factors (typically 37–38 weeks) after confirming fetal lung maturity if <39 weeks; for low‑risk patients, continue expectant management with weekly antenatal testing and reassess at each visit.

Clinical Guardrails / Mimics / Pitfalls

Do not deliver before 37 weeks without clear obstetric indication; avoid expectant management beyond 38 weeks in the presence of any high‑risk factor; do not rely solely on gestational age without risk assessment; do not use a single 24‑hour CGM target <140 mg/dL as a surrogate for comprehensive risk evaluation; and remember that even ideal glycemic control does not eliminate the need for risk‑based timing.

Concrete Clinical Example

A 34‑year‑old with type 2 diabetes for 10 years, HbA1c 7.2%, mild diabetic nephropathy, and ultrasound showing fetal abdominal circumference at the 90th percentile is classified as high risk; delivery is planned at 38 weeks after corticosteroid administration for fetal lung maturity.

Source: Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline, Endocrine Society/European Society of Endocrinology, 2025, https://doi.org/10.1210/clinem/dgaf288

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する